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Summary
CD41CD25highCD127lowforkhead box protein 3 (FoxP31) regulatory T cells
(Treg) are essential for the maintenance of peripheral tolerance. Impaired
Treg function and an imbalance between effector and Tregs contribute to the
pathogenesis of autoimmune diseases. We reported recently that the hepatic
microenvironment is deficient in interleukin (IL)22, a cytokine essential for
Treg survival and function. Consequently, few liver-infiltrating Treg
demonstrate signal transducer and activator of transcription-5 (STAT-5)
phosphorylation. To establish the potential of IL-2 to enhance Treg therapy,
we investigated the effects of very low dose Proleukin (VLDP) on the
phosphorylation of STAT-5 and the subsequent survival and function of
Treg and T effector cells from the blood and livers of patients with
autoimmune liver diseases. VLDP, at less than 5 IU/ml, resulted in selective
phosphorylation of STAT-5 in Treg but not effector T cells or natural killer
cells and associated with increased expression of cytotoxic T lymphocyte
antigen-4 (CTLA-4), FoxP3 and CD25 and the anti-apoptotic protein Bcl-2
in Treg with the greatest enhancement of regulatory phenotype in the
effector memory Treg population. VLDP also maintained expression of the
liver-homing chemokine receptor CXCR3. VLDP enhanced Treg function in
a CTLA-4-dependent manner. These findings open new avenues for future
VLDP cytokine therapy alone or in combination with clinical grade Treg in
autoimmune liver diseases, as VLDP could not only enhance regulatory
phenotype and functional property but also the survival of intrahepatic Treg.
Keywords: autoimmune liver disease, Bcl-2, CTLA-4, interleukin-2, regula-
tory T cells, STAT-5
Introduction
Naturally occurring CD41CD25highCD127lowforkhead box
protein 3 (FoxP31) regulatory T cells (Treg) constitute 5–
10% of peripheral CD41 T cells and maintain peripheral
self-tolerance in rodents and humans [1,2]. Functional
impairment or quantitative deficiency of Tregs has been
described in autoimmune liver diseases (AILD) [3,4],
including those targeted at bile ducts [primary biliary chol-
angitis (PBC) [5,6] or primary sclerosing cholangitis
(PSC)] and hepatocytes [autoimmune hepatitis (AIH)]
[3,7–9]. Current therapies for AILD are non-curative, pro-
vide unsatisfactory control of hepatic inflammation and
require long-term immunosuppressive medications that
carry unfavourable side effects. Thus, autologous Treg ther-
apy is an attractive option for the treatment of AILD that
could provide long-term immune-regulation without daily
medications and global immunosuppression.
Treg survival and function is dependent upon interleukin
(IL)22 [10], which is required for the maintenance of
effective levels of functional Treg in autoimmune diseases
[11–13]. The importance of IL-2 for Treg function has not
been studied closely in autoimmune liver diseases. The cell
surface receptor for IL-2 (IL-2R) is composed of three sub-
units, alpha (IL-2RA, CD25), beta (IL-2RB, CD122) and
common gamma (IL-2RG, CD132). All leucocytes express
IL-2RG constitutively. Natural killer (NK), NK T cells
(NK T) and memory CD81 T cells also express IL-2RB and
Treg express IL-2RA constitutively. IL-2RA is required for
high-affinity IL-2 binding, while IL-2RB and IL-2RG trans-
duce the IL-2 signal [14]. Two major signalling pathways
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conduct IL-2-induced responses: signalling from IL-2RB
leads to the activation of the serine/threonine kinase, AKT,
and to up-regulation of anti-apoptotic molecules such as
Bcl-2, which is required for T cell survival [15]. Signalling
from IL-2RG via Janus kinase 3 (JAK3) leads to signal
transducer and activator of transcription-5 (STAT-5) acti-
vation [16], and is needed for T cell proliferation and dif-
ferentiation and expression of anti-apoptotic molecules
[17,18]. Owing to their high levels of high-affinity CD25,
Treg consume IL-2 competitively, thereby maintaining their
survival and function while suppressing bystander effector
cells [19,20]. Where IL-2 availability is low, such as in the
inflamed hepatic microenvironment, Treg function may be
compromised and may be inadequate to counteract the
activated immune infiltrate.
A number of studies have indicated that treatment with
IL-2 could improve immune-mediated diseases. In rodents,
type 1 diabetes mellitus could be prevented by in-vivo IL-2
administration [21,22]. In humans, low-dose IL-2 therapy
enhanced Treg frequencies and improved outcome in graft-
versus-host disease, vasculitis and type 1 diabetes
[11,23–25]. We recently reported very low levels of IL-2 in
the inflamed human liver [4]. Thus, we considered that
clinical grade IL-2 (Proleukin) therapy might be effective
in AILD.
In this study, we examined the effect of very low dose
Proleukin (VLDP) on the biology of both peripheral and
intrahepatic Treg, focusing upon regulatory phenotype
and function. Successful Treg therapy in AILD would
require not only enhancing Treg phenotype and function,
but also recruitment of peripheral Treg to the inflamed
autoimmune livers. We demonstrate for the first time, to
our knowledge, that VLDP selectively enhances Treg STAT-
5 phosphorylation and subsequently up-regulates func-
tional molecules cytotoxic T lymphocyte antigen-4
(CTLA-4), CD25, FoxP3 and Treg anti-apoptosis marker
Bcl-2 in AILD. VLDP also maintains liver homing chemo-
kine receptor CXCR3 expression on Treg. Importantly,
VLDP enhances the suppressive function of Treg via
CTLA-4, and anti-CTLA-4 can block this effect. Thus, we
demonstrated both phenotype and mechanistic effects of
VLDP on blood and intrahepatic Treg from AILD patients
suggesting that VLDP therapy may enhance immune-
regulatory restoration in AILD.
Materials and methods
Ethics statement
Written informed consent was obtained from all subjects in
this study. Local Research Ethics Committees (LREC) and
the University of Birmingham approved all experimental
protocols (South Birmingham LREC reference: 98 CA/
5192; Walsall LREC reference: 06/Q2708/11).
Blood and liver tissue
Venous blood, collected in ethylenediamine tetraacetic acid
(EDTA) tubes, was obtained from healthy (control) indi-
viduals and individuals with AILD, including AIH, PBC
and PSC. Explanted diseased liver tissue was obtained from
patients undergoing liver transplantation for end-stage
AILD including PBC, PSC and AIH/PBC and AIH/PSC
overlap diseases.
Isolation of liver infiltrating leucocytes (LIL) and
peripheral blood mononuclear cells (PBMC)
LIL were isolated from fresh liver tissue. Briefly, explanted
liver tissue was diced into 5 mm3 cubes, washed with
phosphate-buffered saline (PBS) and then homogenized in
a Seward stomacher 400 circulator (260 rpm, 5 min). The
homogenate was filtered through fine (63 lm) mesh (John
Staniar and Co., Manchester, UK) and the lymphocytes iso-
lated by density gradient separation using Lympholyte (VH
Bio, Gateshead, UK) at 800 g for 20 min. The lymphocyte
layer was collected and washed with PBS. Cell viability was
assessed by trypan blue exclusion. Peripheral blood lym-
phocytes were isolated similarly from whole blood by den-
sity gradient separation using Lympholyte.
Culture of PBMC and LIL
PBMC and LIL were cultured in 24-well plates at a density
of 1 3 106 cells/ml in RPMI-1640 with L-glutamine
medium containing penicillin (100 IU/ml), streptomycin
(100 IU/ml), additional glutamine (2 mM) (GIBCO, Carls-
bad, CA, USA) and 10% human AB serum (TCS Bioscien-
ces, Buckingham, UK) and supplemented with 0 or 5 IU/
ml Proleukin (Aldesleukin) (Novartis, Camberley, UK).
Surface phenotyping of freshly isolated intrahepatic
and peripheral blood lymphocytes with or without
Proleukin treatment
Cell phenotypes were examined by flow cytometry. Dead
cells were identified by staining with the Zombie NIRTM
fixable viability dye (BioLegend, San Diego, CA, USA) or
e506 viability dye (eBioscience, San Diego, CA, USA) prior
to staining with antibodies. To analyse expression of surface
antigens, cells were incubated on ice for 30 min with anti-
bodies against CD3, CD4, CD8, CD25, CD127 and markers
of interest or isotype-matched control antibodies in 2%
fetal bovine serum (FBS) (Sigma Aldrich, Poole, UK)
diluted in PBS. After washing with 2% FBS (Sigma
Aldrich), cells were fixed for 10 min with 3% formaldehyde
solution (Sigma Aldrich). To analyse expression of intracel-
lular proteins, cells were fixed and stained using the FoxP3/
transcription factor staining set (eBioscience), according to
the manufacturer’s instructions. Antibodies against surface
markers (CD3, CD4, CD8 CD25, CD127) were generally
added together with antibodies against intracellular
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markers of interest during the permeabilization and intra-
cellular staining steps. Data were acquired using a CyAN
ADP flow cytometer (Dako, Glostrup, Denmark). Single
fluorophore-labelled anti-mouse immunoglobulin (Ig)Gj/
negative control (FBS) compensation particles (BD Bio-
sciences, Franklin Lakes, NJ, USA) were used for compen-
sation. Data were analysed offline using FlowJo (TreeStar
Inc., Ashland, OR, USA).
The anti-human antibodies used in flow cytometric
analysis of marker expression included: anti-CD3-
phycoerythrin-cyanin 7 (PE-Cy7) (SK7; BD Biosciences),
anti-CD4-peridinin chlorophyll (PerCP/Cy5.5 (RPA-T4;
eBioscience), anti-CD4-Viogreen (VIT4; Miltenyi Biotec),
anti-CD8-PE-CF594 (RPA-T8; BD Biosciences), anti-
CD25-BV421 (M-A251; BD Biosciences), anti-CD45Ra-
allophycocyanin (APC)-Vio770 (T6D11; Miltenyi Biotec),
anti-CD127-fluorescein isothiocyanate (FITC) (eBioRDR5;
eBioscience), anti-CCR7-PE-CF594 (150503; BD Bioscien-
ces), anti-granzyme B-PE (GB11; eBioscience), anti-CTLA-
4-PE (BN13; BD Biosciences), anti-Bcl-2-PE (100; BioLe-
gend), anti-FoxP3-APC (PCH101; eBioscience) anti-CD39-
PE (A1; eBioscience), anti-T cell immunoglobulin and
mucin domain-containing-3 (TIM3)-PE (F38-2E2; eBio-
science), anti-OX40-PE (ACT35; BD Biosciences), anti-
CD69-PE (FN50; Miltenyi Biotec), anti-2B4-PE (REA112;
Miltenyi Biotec), anti-CD73-APC (AD2; eBioscience), anti-
CD137-APC (4B4-1; Miltenyi Biotec), anti-glucocorticoid-
induced tumour necrosis factor receptor (GITR)-APC
(DT5D3; Miltenyi Biotec), anti-lymphocyte-activation
gene 3 (LAG3)-APC (3DS223H; eBioscience) and anti-PD-
1-APC (PD1.3.1.3; Miltenyi Biotec).
Analysis of STAT-5 phosphorylation in response to IL-2
To examine responsiveness of PBMC or LIL to IL-2, cells in
RPMI were stained with anti-CD127-FITC (eBioRDR5;
eBioscience), anti-CD20-Viogreen (LT20; Miltenyi Biotec)
and anti-CD56-pacific blue (HCD56; Biolegend) for 10
min at room temperature. Cells were then stimulated for
10 min at 378C with Proleukin (0-1000 IU/ml). Cells were
fixed and permeabilized with BD Biosciences Phosflow buf-
fers I and III according to the manufacturer’s instructions
then stained for 1 h at room temperature in 2% FBS
(Sigma) with anti-pSTAT-5 (Y694)-AlexaFluor 647 (47/
STAT-5), anti-CD3-PeCy7 (SK7), anti-CD8-PE-CF594
(RPA-T8) (all from BD Biosciences), anti-CD4-
PerCPCy5.5 (RPA-T4; eBioscience) and anti-CD25-PE
(3G10; Miltenyi Biotec). All data were acquired using a
CyAn ADP (Dako) flow cytometer and analysed using
FlowJo (Tree Star) software.
Analysis of suppression of autologous T responder
cell division by Treg in response to IL-2
CD41CD251CD127– Treg and CD4
1CD25–CD1271
responder T cells were isolated by flow sorting following
prior enrichment of total CD41 T cells from PBMC using
magnetic negative selection (Biolegend). Treg were cultured
overnight with or without Proleukin (5 IU/ml). Responder
T cells were labelled with cell trace violet (molecular
probes; Thermofisher, Waltham, MA, USA) and cultured
overnight without stimulation. Dendritic cells (DC) were
derived from monocytes that were isolated from healthy
donor PBMCs by magnetic negative selection (StemCell
Technologies, Vancouver, Canada) and cultured for 5–7
days in IL-4 (500 IU/ml; Miltenyi Biotec) and granulocyte–
macrophage colony-stimulating factor (GM-CSF) (800 IU/
ml; Berlex Laboratories, Richmond, CA, USA). DCs and
Treg were washed to remove cytokines and co-cultured for
5 days with responder T cells in the presence of 05 lg/ml
anti-CD3 (clone OKT3; Biolegend) with or without 40 lg/
ml anti-CTLA-4. Division of responder T cells under 50
lg/ml CTLA-4-Ig (abatacept) was also monitored. Cells
were cultured at a ratio of 1 DC : 20 T cells with a 1
Treg : 25 responder T cell ratio. At 5 days, cell trace violet
dilution was measured by flow cytometry and the statistics
percentage division and division index (the average num-
ber of cell divisions undergone by a cell in the original pop-
ulation) calculated using the FlowJo proliferation analysis
platform.
Statistical analysis
Statistical significance between two variables across
multiple subsets was tested by two-way two-tailed analy-
sis of variance (ANOVA) with Bonferroni’s post-hoc analy-
sis. Significance between two populations was tested by
paired t-test and between multiple treatments by one
way ANOVA with Bonferroni’s post-hoc analysis. Analysis
and graphical representation was performed using
GraphPad Prism version 5 (GraphPad software, San
Diego, CA, USA).
Results
Phosphorylation of STAT-5 occurs selectively in Treg
at very low doses of Proleukin in normal blood
To analyse the responsiveness of different leucocyte popula-
tions to IL-2 (Proleukin) and identify a dose that would
phosphorylate STAT-5 selectively in Treg, we administered
Proleukin at doses of between 0 and 1000 IU/ml to PBMC
from healthy control bloods and examined phosphoryla-
tion of STAT-5 in Treg and other leucocyte populations:
(Fig. 1a and Supporting information, Fig. 1). With the
exception of B cells, all cell types responded to Proleukin at
10 IU/ml and above (Fig. 1a). However, at 1 IU/ml, 25% of
Treg showed measurable pSTAT-5 expression, while there
was no up-regulation in pSTAT-5 in other subsets. More
than 75% of Treg demonstrated pSTAT-5 induction at 10
IU/ml; however, this dose also led to phosphorylation of
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STAT-5 in other CD41 T cells and CD56bright NK cells.
Nevertheless, this pSTAT-5 induction in non-Tregs at this
concentration was barely above baseline, as indicated by
pSTAT-5 median fluorescence intensity (MFI) (Fig. 1a).
Most importantly, at 2–4 IU/ml, Treg pSTAT-5 MFI was
23–36-fold above baseline, but there was no increase in
pSTAT-5 MFI for other subsets (Fig. 1a). Thus, we observed
that with a very low dose of Proleukin (VLDP) (< 5 IU/
ml), selective phosphorylation of STAT-5 in Treg could be
achieved. The characteristics of the control cohort used in
these and subsequent phenotyping studies in this paper are
given in Table 1.
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Fig. 1. Very low dose interleukin (IL)22 up-regulates phosphorylated signal transducer and activator of transcription-5 (pSTAT-5) selectively in
peripheral and liver-infiltrating regulatory T cells (Treg) from patients with autoimmune liver disease. Peripheral blood mononuclear cells (PBMCs)
from control bloods (a, n 5 3) or autoimmune liver disease patient bloods [b, autoimmune hepatitis (AIH) remission, n 5 5; AIH relapse, n 5 4;
primary biliary cholangitis (PBC), n 5 3; and primary sclerosing cholangitis (PSC), n 5 3] and liver-infiltrating lymphocytes from explanted livers
of patients with autoimmune liver disease (c, n 5 4) were stimulated for 10 min with IL-2 (Proleukin) at doses in the range 0–1000 IU/ml and the
expression of p(Y694) STAT-5 determined by flow cytometry for each leucocyte population. Graphs summarize pSTAT-5 expression, quoted as
percentage of positive cells or median fluorescence intensity (MFI). Data are mean6 standard error of the mean (s.e.m.).
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Very low doses of Proleukin induce selective
phosphorylation of STAT-5 in intrahepatic and
peripheral blood Treg of patients with autoimmune
liver diseases
PBMC from AIH, PBC and PSC patients were treated with
Proleukin in the range of 0–100 IU/ml. Similar to controls,
Treg of AIH patients [both remission and flare-up (relapse)],
PBC patients and PSC patients demonstrated a selective
pSTAT-5 induction at doses below 10 IU/ml, especially at
5 IU/ml (Fig. 1b and Supporting information, Fig. 2). We
then treated human LIL isolated from explanted autoimmune
liver disease tissues with 0–100 IU/ml Proleukin, and again
selective pSTAT-5 enhanced induction was seen in Treg at
doses below 10 IU/ml (Fig. 1c). Descriptions of all AILD
blood and liver explant donors whose PBMC and LIL were
used in these and subsequent studies in this paper to address
the effect of IL-2 on phenotype are given in Tables 1 and 2
[blood donors were: AIH5 20 (aged 4446 138 years, dis-
ease in remission5 14, disease in flare up/relapse5 6);
PSC5 3 (aged 5806 173 years); PBC5 10 (aged 5406
96 years); control5 9 (aged 5516 119 years)]. Liver donors
were: PBC5 5 (aged 5946 64 years); PSC5 2 (aged 5156
233 years); AIH overlap5 2 (aged 3806 240 years), PBC/
AIH overlap5 1; and PSC/AIH overlap5 1).
Very low doses of Proleukin induce Treg functional
markers CTLA-4, CD25 and FoxP3 selectively in both
blood and intrahepatic Treg
Having found 5 IU/ml Proleukin by dose titration to be the
optimal concentration to induce a selective STAT-5 response
in blood and liver Treg of AILD patients, we determined the
effect of 5 IU/ml Proleukin on T cell phenotype and func-
tion. PBMC and LIL from AILD patients were exposed to 0
IU/ml or 5 IU/ml Proleukin for 18 h and effects on markers
of T cell activation and Treg function by T cell subsets were
assessed; 5 IU/ml Proleukin increased significantly the levels
of CD25, CTLA-4 and FoxP3 on peripheral blood Treg of
AILD patients (Fig. 2a and Supporting information, Fig. 3).
In liver, basal expressions of CTLA-4, CD25 and FoxP3 on
Treg were higher than in blood and similar to those observed
in blood following Proleukin exposure (Fig. 2a). There were
clear trends towards increased expression of the Treg markers
CD25 and FoxP3 with VLDP in liver Treg from PBC, PSC
and AIH, supporting potentiation of Treg in the liver in
settings of the AILDs (Fig. 2a and Supporting information,
Fig. 3). These observations are consistent with and also
reflective of upstream pSTAT-5 induction by VLDP in liver
Treg (Fig. 1c). Frequencies of expression of CD25, CTLA-4
and FoxP3 were largely not altered in blood or liver Treg by
VLDP (Supporting information, Fig. 4).
Because we noticed that 18 h exposure to Proleukin led to
STAT-5 phosphorylation in CD251CD1271CD41 T cells that
mirrored that in Treg (CD25
1CD127–CD41) (both frequency
and MFI) (Supporting information, Fig. 5), we evaluated theT
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effect of 18-h VLDP on the expression of CD25, CTLA-4 and
FoxP3 by the CD251CD1271CD41 T effector cell population
in the blood of AILD patients (Fig. 2b). Importantly, despite
phosphorylation of STAT-5, this subset, unlike Treg, did not
up-regulate CD25, CTLA4 or FoxP3 (Fig. 2b).
We then investigated the effect of VLDP on the expression
by peripheral and liver-infiltrating Treg of tumour necrosis
factor (TNF) receptor superfamily members CD137, OX40
and GITR. Culture in 5 IU/ml Proleukin helped to maintain
expression frequencies of CD137 and GITR on peripheral
Treg over 18 h and promoted an increase in the frequency of
OX40 expressing peripheral Treg (Fig. 3a and Supporting
information, Fig. 3). Exposure to VLDP did not influence
the frequency of expression of these markers on liver-
infiltrating Treg (Fig. 3a). We also investigated the impact of
VLDP on Treg-associated surface markers, including CD39,
CD73 and LAG3. Proleukin 5 IU/ml had no effect on the
expression frequency of any of these molecules (Fig. 3b and
Supporting information, Fig. 3): high expression of CD39
was maintained, CD73 remained low-expressed and TIM3
and LAG3, which were not detected at baseline, were not
induced by Proleukin treatment on Treg. Also, VLDP did not
alter expression of the activation marker, CD69 or the
immune checkpoint and programmed cell death receptor-1
(PD-1) on CD41 or CD81 T cells or Treg (Fig. 3c and Sup-
porting information, Fig. 3). Consistent with a lack of
pSTAT-5 induction in CD81 T cells under VLDP, 5 IU/ml
Proleukin did not affect expression of granzyme B or activa-
tion marker 2B4 by CD81 T cells (Fig. 3c and Supporting
information, Fig. 3).
Very low dose Proleukin enhances Treg suppressive
potential in a CTLA-4-dependent manner across all
autoimmune liver diseases
Having established that VLDP 5 IU/ml enhances Treg expres-
sion of regulatory functional molecules we sought to verify
that these changes in phenotype associate with improve-
ments in Treg function. We tested whether exposure to
VLDP could increase the ability of Treg to suppress the divi-
sion of autologous CD25–CD41 T effector cells. We used a
system of anti-CD3 together with monocyte-derived DC to
supply co-stimulatory ligands. This system was chosen over
conventional anti-CD3/CD28 bead activation of T cell pro-
liferation in order that the functional impact of antigen-
presenting cell–Treg contact-dependent mechanisms of sup-
pression such as involving CTLA-4 might be studied. Pre-
treatment of Treg with Proleukin reduced significantly the
division of T responder cells from control individuals cul-
tured 25 : 1 with autologous Treg (Fig. 3d,e). This elevated
suppressive potential of VLDP-treated Treg was overcome in
the presence of anti-CTLA-4 (Fig. 3d,f). Consistent with our
observations that CTLA-4-Ig can reduce T responder divi-
sion (Supporting information, Fig. 6a), anti-CTLA-4 also
tended to increase T responder division in the presence of
untreated Treg (Fig. 3f). We observed the same trends of
improved Treg function involving contribution from CTLA-4
with VLDP treatment of Treg in both cases of AILD patients
tested (Supporting information, Fig. 6b).
Very low dose Proleukin treatment does not alter
liver homing CXCR3 expression by peripheral blood
Treg in autoimmune liver diseases
Regulatory T cell homing to the site of liver inflammation is
crucial for the success of Treg therapies, thus we examined
the crucial liver-homing chemokine receptor, CXCR3, on
blood Treg of autoimmune liver disease patients. De-novo
expression levels (MFI and frequency) of CXCR3 were simi-
lar in patients with AIH compared to controls (Fig. 4a).
Importantly, VLDP 5 IU/ml did not have any impact upon
CXCR3 expression in AIH patients over 18 h or up to 3 days
(Fig. 4b,c). Peripheral Treg from PSC and PBC patients also
showed no change in their CXCR3 expression with sustained
culture in VLDP (Fig. 4b,d), thus VLDP therapy may be
applicable for all three autoimmune liver diseases without
impairing the recruitment capacity of Treg.
Very low dose Proleukin treatment increases total Treg
frequencies and promotes the strongest Treg
suppressive phenotype in the CD45RA–CCR7–
population of Treg
We noted that the CD251CD127–FoxP31 Treg population,
as a proportion of total CD41 T cells, increased
Table 2. Demographic, histology and treatment details of patients in the liver explant cohort
Disease Age (years) Sex Explant history Treatment before transplantation
PBC 51 M Moderate fibrosis Ursodeoxycholic acid
PBC 63 F Established cirrhosis Ursodeoxycholic acid
PBC 65 F Established cirrhosis Ursodeoxycholic acid
PBC 64 F Established cirrhosis Ursodeoxycholic acid
PBC 54 F Established cirrhosis Ursodeoxycholic acid
PSC 68 M Established cirrhosis
PSC 35 M Established cirrhosis
PBC/AIH overlap 55 F Established cirrhosis Ursodeoxycholic acid
PSC/AIH overlap 21 F Established cirrhosis
AIH 5 autoimmune hepatitis; PBC 5 primary biliary cholangitis; PSC 5 primary sclerosing cholangitis.
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Fig. 2. Effect of very low dose interleukin (IL)22 on expression of IL-2-regulated regulatory T cells (Treg) functional markers CD25, cytotoxic T
lymphocyte antigen-4 (CTLA-4) and forkhead box protein 3 (FoxP3) by Treg cells from blood and liver. Peripheral blood mononuclear cells
(PBMCs) from patients with autoimmune hepatitis (AIH) (n5 5), primary sclerosing cholangitis (PSC), (n5 3) and primary biliary cholangitis
(PBC), n5 6) and liver-infiltrating leucocytes from autoimmune liver diseases (AILD) livers were exposed to 0 or 5 IU/ml IL-2 (Proleukin) for
18 h and the median fluorescence intensity of CD25, CTLA-4 and FoxP3 examined by flow cytometry for (a) CD4, CD8 and Treg cells and (b)
CD4 subsets defined by CD25 versus CD127 expression. Data are mean6 standard error of the mean (s.e.m.). Significant effects of IL-2 analysed
by paired t-tests (a) and two-way analysis of variance (ANOVA) with Bonferroni’s post-hoc test (b) are shown.
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Fig. 3. (a–c) Effect of very low dose interleukin (IL)22 on regulatory T cells (Treg) and T effector functional and activation phenotypes.
Peripheral blood mononuclear cells (PBMCs) from patients with autoimmune hepatitis (AIH) and liver infiltrating leucocytes from autoimmune
liver diseases (AILD) livers were exposed to 0 or 5 IU/ml IL-2 (Proleukin) for 18 h and the expression of functional and activation markers by T
cell subsets analysed by flow cytometry. (a) Expression of tumour necrosis factor (TNF) receptor superfamily members by blood and liver Treg.
(b) Expression of CD39, CD73, T cell immunoglobulin and mucin domain-containing-3 (TIM3) and lymphocyte-activation gene 3 (LAG3) by
blood Treg. (C) Expression of CD69, programed death 1 (PD-1), 2B4 and granzyme B by blood CD4, CD8 and Treg. Data are mean6 standard
error of the mean (s.e.m.) for 2–6 donors. (d–f) Very low dose IL-2 increases Treg suppressive ability in a mechanism involving cytotoxic T
lymphocyte antigen-4 (CTLA-4). CD41CD251CD127– Treg and autologous CD4
1CD25– T responder cells were isolated from PBMC of control
individuals. T responders were labelled with cell trace violet and following overnight exposure of Treg to 0 or 5 IU/ml Proleukin were co-cultured
with the Treg in the presence of anti-CD3 and dendritic cells, with or without CTLA-4 blockade. Cell trace violet dilution indicating T responder
cell division was analysed by flow cytometry at 5 days. (d) Representative flow cytometry histograms of T responder division showing percentage
division. (e) Division index summary data (n5 3) of T responders in the presence of Treg pretreated with 0 or 5 IU/ml Proleukin. (f) Division
index summary data (n5 3) of T responders in the presence of Treg pretreated with 0 or 5 IU/ml Proleukin with or without anti-CTLA-4. Data
are mean6 standard error of the mean (s.e.m.). Significant effects of IL-2 and CTLA-4 blockade analysed by paired t-tests (e) and one-way
analysis of variance (ANOVA) with Bonferroni post-hoc test (f) are shown.
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significantly with culture in VLDP up to 3 days in AILD
patients and controls (Fig. 5a). No differences in frequency
were seen between any of the patient or control groups at
either condition. The naive (CD45RA1CCR71) subset of
Treg has been reported to maintain the Treg-specific deme-
thylated region (TSDR) following expansion, making them
an attractive option for Treg cell immunotherapy [26,27];
thus, we evaluated the effect of 3 days VLDP on frequencies
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of each of the maturation subsets of CD251CD127–FoxP31
Treg defined by CD45RA and CCR7 expression [28]. VLDP
did not alter the proportions of the maturation subsets in
any AILD patient cohorts (AIH, PSC, PBC) or controls (Fig.
5b,c). None the less, as before, VLDP increased significantly
the expression of IL-2 regulated markers CTLA-4, CD25 and
FoxP3 on Treg from all subsets. Overall, across AIH, PSC,
PBC and control, the effector memory (CD45RA–CCR7–)
subset of CD251CD127–FoxP31 Treg cells showed the great-
est induction of Treg functional markers with VLDP treat-
ment (Fig. 5d).
Liver-infiltrated Treg are restricted predominantly to
the CD45RA–CCR7– population
Blood CD251CD127–FoxP31 Treg subsets in AILD patients
are comprised of approximately 60% effector memory
(CD45RA–CCR7–), 15–20% central memory
(CD45RA–CCR71) and 15–20% naive (CD45RA1CCR71)
populations. Because VLDP increased significantly the
expression of Treg functional markers CTLA-4, CD25 and
FoxP3, especially in the CD45RA–CCR7– subset of Treg, we
investigated the frequency of these subsets in the inflamed
human liver. We found that the effector memory
CD45RA–CCR7– subset of CD251CD127–FoxP31 Treg popu-
lation is increased significantly (95%) in the inflamed human
livers compared to peripheral blood (60%) (Fig. 6a,b).
Very low dose Proleukin up-regulates expression of
the anti-apoptotic molecule Bcl-2 on Treg compared
to effector T cells
The anti-apoptotic protein Bcl-2 is regulated differentially
in effector T cells versus Treg [29]. To assess whether VLDP
alters Bcl-2 expression, lymphocytes from AILD patients
and controls were treated with 5 IU/ml Proleukin for 18 h
or 3 days and their Bcl-2 expression was evaluated. While
expression by total CD41 and CD81 T cells was not altered
up to 3 days, VLDP tended to increase blood Treg
expression of Bcl-2 by 18 h (Fig. 7a). By 3 days, a signifi-
cant twofold up-regulation of Bcl-2 expression in Treg of
patients with AIH was seen (Fig. 7b), and the same trend
was observed in PSC and PBC (Fig. 7c). We also verified
the effect of VLDP on Bcl-2 in AILD liver Treg at 3 days.
Consistent with the response found in blood, we observed
selective up-regulation of Bcl-2 in liver Treg (Fig. 7d), which
were of PBC and PSC disease backgrounds. In view of the
STAT-5 response by the CD41CD251CD1271 subset with
sustained exposure to VLDP, we analysed the effect of
VLDP on Bcl-2 expression by each CD41 T cell subset,
defined by CD25 versus CD127 expression at 3 days in
blood (Fig. 7e,f) and liver (Fig. 7g), and saw that in blood
the CD41CD251CD1271 subset also showed increased
Bcl-2 expression with Proleukin; however, the relative fold
increase in Bcl-2 expression by this effector subset was less
compared to that observed for Treg.
Discussion
IL-2 is a crucial cytokine for survival and function of T cells,
including Treg. We demonstrated in this study that very low
dose clinical grade IL-2 (Proleukin) induces STAT-5 phos-
phorylation selectively in CD41CD251CD127– Treg from
blood and liver of patients with AILD and is accompanied
not only by a series of phenotypic and functional changes,
but also up-regulates Bcl-2 to support Treg survival. These
data support existing evidence in autoimmune conditions
such as diabetes and vasculitis that VLDIL-2 administration
contributes to the maintenance of self-tolerance by increas-
ing Treg frequency [23,25,30]. Our study extends the poten-
tial of VLDP therapy to the treatment of autoimmune liver
diseases.
Administration of the IL-2 or the IL-2 : anti-IL-2 mono-
clonal antibody complex reduces autoimmune disease in
rodent models [31,32]. Studies in vasculitis, graft-versus-
host disease, systemic lupus erythematosus and type 1
Fig. 5. Low dose Proleukin treatment increases total regulatory T cell (Treg) frequencies and promotes the strongest Treg phenotype in the
CD45Ra–CCR7– effector memory population of Treg. (a) Peripheral blood mononuclear cells (PBMCs) from controls, autoimmune hepatitis
(AIH), primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC) patients were exposed to 0 or 5 IU/ml IL-2 (Proleukin) for 3
days and the frequency of CD41CD251CD127–forkhead box protein 3 (FoxP3)1 Treg assessed by flow cytometry. Significant effects of IL-2 were
analysed by two-way analysis of variance (ANOVA) with Bonferroni’s post-hoc analysis. Frequencies of memory and naive subsets of
CD41CD251CD127–FoxP31 Treg as defined by CD45Ra and CCR7 expression were also determined at 3 days by flow cytometry. (b)
Representative flow cytometry density plot of CCR7 versus CD45Ra for one PSC donor after 3 days of culture in 0 or 5 IU/ml Proleukin and
summary data for all donors (c). Significant effects of IL-2 on the frequencies of the different memory/naive subsets were compared by two-way
ANOVA with Bonferroni’s post-hoc analysis, but no significant differences were identified. (D) Expression of cytotoxic T lymphocyte antigen-4
(CTLA-4), CD25 and FoxP3 by each memory or naive subset of Treg. Data are mean6 standard error of the mean (s.e.m.) (control (n5 3), AIH
(n5 4), PSC (n5 3) and PBC (n5 6), central memory (CM) (CD45Ra–CCR71); naive (CD45Ra1CCR71); terminally differentiated effector
memory (TEMRA) (CD45Ra1CCR7–); effector memory (EM) (CD45Ra–CCR7–). Effects of 5 IU/ml Proleukin on the expression of these
markers by each subset were analysed by two-way ANOVA with Bonferroni’s post-hoc tests. Stars indicate where there was a significant effect of IL-2
upon the expression of the marker by the subset (*P< 005; **P< 001; ***P< 0001; ****P< 00001). Braces with stated P-values indicate
significant differences in expression by the subsets under 5 IU/ml Proleukin conditions. With the exception of CTLA-4 expression by naive versus
EM cells in PSC patients, or of FoxP3 expression by CN versus naive, CM versus TEMRA or TEMRA versus effector memory in PBC patients,
there were no significant differences between the subsets for expression of any marker in the absence of IL-2 treatment.
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diabetes suggest that an IL-2 dose range of 03–30 3 106
IU/m2 is well tolerated, and achieves a preferential increase
in the percentage of Treg with no induction of effector T
cell activation [23,25,33,34]. The dose range we have
identified working with clinical grade IL-2 (Proleukin) in
vitro is similar to other investigators, who have applied
VLDP in autoimmune diseases [11,23,25,34]. High-dose
IL-2 is approved in cancer therapy, where it promotes
tumour killing by activating NK cells and CD41 and CD81
effector T cells [12]; however, pulmonary vascular leakage
occurs as a side effect to this treatment [35]. By avoiding
the activation of effector cells, VLDP should be safe for
clinical application in general. Indeed, a former dose esca-
lation study of low-dose IL-2 for treatment of graft-versus-
host disease reported very few adverse events except skin
induration in a minority of study patients. Other poten-
tially linked rare side effects include fatigue, malaise, fever,
thrombocytopenia and raised serum creatinine [23].
Despite this, it is prudent that low-dose Proleukin therapy
in a hospital setting be restricted to patients with normal
cardiac and pulmonary function.
IL-2 is crucial for Treg function. Binding of IL-2 to IL-
2RA (CD25) on Treg leads to phosphorylation of STAT-5,
resulting in up-regulation of FoxP3 [36] and functional
surface markers. FoxP3 is essential for Treg development
and function, as evident from the occurrence of immuno-
dysregulation polyendocrinopathy enteropathy X-linked
(IPEX) syndrome in patients with mutations in FoxP3
[37,38]. Although Treg do not secrete IL-2, their high
expression of CD25 allows them to consume and respond
to low concentrations of exogenous IL-2 [39,40].
CD41CD25–CD1271 effector T cells express intermediate-
affinity IL-2 receptors, IL-2RB and IL-2RG constitutively;
thus, they require higher concentrations of IL-2 for activa-
tion in the absence of T cell receptor (TCR) engagement
[41]. Importantly, we observed that applying VLDP of less
than 5 IU/ml could enhance FoxP3 selectively in Treg com-
pared to CD81, CD41CD25–CD1271/– and
CD41CD251CD1271 effector T cells from the blood and
liver of patients with AILD. There was no noticeable activa-
tion of these effector subsets based on expression of CD69,
granzyme B or 2B4.
CTLA-4 is an essential functional marker on Treg [42]. It
functions by removing its co-stimulatory ligands, CD80/
CD86, from antigen-presenting cells by transendocytosis
[43]. Mice deficient in CTLA-4 display an autoimmune
phenotype and immune dysregulation is observed in
patients with CTLA-4 polymorphisms [44]. Our data sug-
gest that VLDP up-regulates CTLA-4 expression by Treg,
but has no impact on CD41CD251CD1271 effector T
cells. Furthermore, we identify that CTLA-4 is a significant
mediator in the mechanisms by which VLDP confers
enhanced suppressive potential to Treg; VLDP also main-
tains Treg functional markers such as GITR and OX40.
We have reported recently that the inflamed liver micro-
environment is deficient in IL-2 protein and that activated
intrahepatic T cells are the main source of IL-2 in the
human liver [4]. Local consumption of IL-2 by immune
cells, including Treg, creates a microenvironment that is
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Fig. 6. Comparison of the frequencies of memory and naive
regulatory T cell (Treg) populations in blood and liver. (a)
Frequencies of memory and naive subsets of CD41CD251CD127–
Treg as defined by CD45Ra and CCR7 expression were determined by
flow cytometry for peripheral blood mononuclear cells (PBMCs) and
liver infiltrating lymphocytes from patients with autoimmune liver
diseases (AILD). (a) Representative flow cytometry density plot for
expression of CD45Ra and CCR7 by blood and liver infiltrating Treg
showing the four subsets including: central memory (CM)
(CD45Ra–CCR71); naive (CD45Ra1CCR71); terminally
differentiated effector memory (TEMRA) (CD45Ra1CCR7–); effector
memory (EM) (CD45Ra–CCR7–). (b) Summary frequencies for each
memory and naive subset in blood [n5 6 donors with autoimmune
hepatitis (AIH)] and liver [n5 4 donors with AILDs including
primary sclerosing cholangitis (PSC) and primary biliary cholangitis
(PBC)]. Data are mean6 standard error of the mean (s.e.m.).
Significance was tested by non-matched two-way analysis of variance
(ANOVA) and showed significant interaction for subset versus tissue
P< 00001. Bonferroni’s post-hoc tests identified significant
differences between blood and liver in the frequencies of CM and
EM cells, as indicated. There was no significant effect of tissue on
subset distribution but there was a significant effect of subset
P< 00001.
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deficient in IL-2 to the level that it is unable to support Treg
function. This finding is consistent with our previous
observation that only some of the FoxP31 Treg in the liver
undergo STAT-5 phosphorylation [45]. We observed that
liver Treg had higher baseline expressions of CTLA-4, CD25
and FoxP3 than peripheral Treg and these were equivalent
to levels seen on peripheral blood Treg after IL-2 stimula-
tion. A higher baseline expression probably reflects the
more activated, effector state of liver versus blood lympho-
cytes. Liver Treg also expressed higher levels of the TNF
receptor superfamily members CD137, OX40 and GITR
than peripheral Treg, and comparing our current data in
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Fig. 7. Very low dose interleukin (IL)-2 up-regulates Bcl-2 expression in regulatory T cells (Treg) from blood and liver. Peripheral blood
mononuclear cells (PBMCs) from autoimmune hepatitis (AIH) patients (a,b,e), primary sclerosing cholangitis (PSC) patients (c,f), primary
biliary cholangitis (PBC) patients (c,f) and liver-infiltrating lymphocytes from autoimmune liver diseases (AILD) livers (d,g) were exposed to 0
or 5 IU/ml IL-2 (Proleukin) for 18 h (a) or 3 days (b–g) and the median fluorescence intensity (MFI) of Bcl-2 on CD4, CD8 and Treg examined
by flow cytometry (a–d). (E–G) Day 3 Bcl-2 expression by blood (e,f) and liver (g) CD41 T cell subsets defined by CD25 versus CD127
expression. Data are mean6 standard error of the mean (s.e.m.). Significant effects of IL-2 were assessed by paired t-tests (a–d) and two-way
analysis of variance (ANOVA) (e–g).
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peripheral blood with our previous phenotyping of intra-
hepatic Treg in AILD we identify that CD69 (40%), LAG3
(20%), Tim3 (5%) and cytolytic granzyme B (5%) are also
all up-regulated on Treg in the liver compared to periphery
(< 5% in peripheral blood) [4]. This is in contrast to
CD39 and PD-1, which are expressed similarly on Treg at
both sites [4].
The effectiveness of Treg function within the inflamed tis-
sue setting might be compromised due to the action of
inflammatory cytokines such as IL-6, IL-8, IL-12, IFN-g
and IL-1bg [4], which can enhance effector T cell activa-
tion and proliferation at the expense of Treg. Thus, exoge-
nous IL-2 such as VLDP might help to counteract these
inflammatory signals [46,47]. CTLA-4-mediated Treg sup-
pressive function is via depletion of CD80/86 through
transendocytosis [43]. Excitingly, we observed that VLDP
enhances Treg suppressive function via CTLA-4.
Recruitment of peripheral blood Treg to the site of
hepatic inflammation is dependent upon expression of the
tissue-homing CXCR3 chemokine receptor [45,48,49]. We
found expression of CXCR3 on approximately 50% of
peripheral blood Treg from AILD patients, comparable to
controls, suggesting that cells from patients, even on
immunosuppression, retain the liver-homing receptors for
recruitment. Moreover, we report that CXCR3 expression
was unaffected by VLDP, implying that Treg of patients on
VLDP therapy would retain the capability to home to
inflamed hepatic lobules and portal tracts. We have
reported recently that human liver-infiltrating Treg are
mainly of CD45RA–CCR7– phenotype [4]. Our findings
now demonstrate that exogenous VLDIL-2 up-regulates
Treg functional markers predominantly in this effector
(suppressor) population in all types of AILD. A recent
study also described high expression of CXCR3 in CD41 T
cells in early-stage PBC, which was associated with
increased demethylation of the CXCR3 promoter. This up-
regulation was most striking in the activated memory
CD45RO1 population [50]. Taken together, these data sug-
gest that CD41 Treg from patients with AILD will recruit to
the human liver and be potentiated functionally by IL-2
therapy.
Treg depend upon IL-2 for expansion and survival and
cells undergo apoptosis upon IL-2 deprivation [51]. Bcl-2
is a critical target in IL-2 signalling [18,52], helping to pro-
tect responding cells from apoptosis. A recent study also
confirmed that use of a pan-Bcl-2 inhibitor leads to pro-
found down-regulation of FoxP3 and CTLA-4 and a reduc-
tion in the suppressive function of Treg [53]. We
demonstrated that VLDP enhances Bcl-2 expression selec-
tively in Treg but not CD8
1 T cells or CD41 T effector cells
from both peripheral blood and liver. This is an important
observation because enhanced survival of immune-
regulatory Treg is critical to the maintenance of tolerance.
In conclusion, our findings provide compelling evidence
to support the design of Treg-directed Phase I and II clinical
trials administering VLDP as a cytokine monotherapy or in
combination with autologous Treg cell therapy in AILD.
Given its short half-life, regular doses of VLDP may be
required to maintain efficacy.
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Fig. S1. Flow cytometry gating strategy for the analysis of
signal transducer and activator of transcription-5 (STAT-
5) expression by regulatory T cells (Treg) and eight other
immune cell subsets.
Fig. S2. Very low dose interleukin (IL)22 selectively up-
regulates signal transducer and activator of transcription-
5 (STAT-5) in peripheral regulatory T cells (Treg) from
autoimmune hepatitis (AIH) and primary biliary cholan-
gitis (PBC) patient bloods. Peripheral blood mononuclear
cells (PBMCs) from patients with AIH, PBC or primary
sclerosing cholangitis (PSC) were stimulated for 10 min
with IL-2 (Proleukin) 0-100 IU/ml and the percentage
expression of phosphorylated (Y694)STAT5 by each leu-
cocyte population assessed by flow cytometry at each IL-2
dose. Data are mean6 standard error of the mean
(s.e.m.) for five donors (AIH remission), four donors
(AIH relapse) and three donors (PBC and PSC).
Fig. S3. Flow cytometry gating strategy (a) to define
CD4, CD8 and regulatory T cell (Treg) populations and
representative overlays (b,d) for markers of T cell activa-
tion and function on CD4, CD8 and Treg in autoimmune
liver disease (AILD) blood [autoimmune hepatitis (AIH)]
and liver [primary sclerosing cholangitis (PSC)] following
18 h exposure to Proleukin 5 IU/ml.
Fig. S4. Effect of very low dose interleukin (IL)22 on
expression of IL-2-regulated regulatory T cell (Treg) func-
tional markers CD25, cytotoxic T lymphocyte antigen-4
(CTLA-4) and forkhead box protein 3 (FoxP31) by CD4,
CD8 and Treg cells from blood and liver. Peripheral blood
mononuclear cells (PBMCs) from patients with auto-
immune hepatitis (AIH), primary sclerosing cholangitis
(PSC) and primary biliary cholangitis (PBC) and liver
infiltrating lymphocytes from autoimmune liver disease
(AILD) livers were exposed to 0 or 5 IU/ml IL-2 (Proleu-
kin) for 18 h and the percentage expression of CD25,
CTLA-4 and FoxP3 by CD41, CD81 and Treg cells exam-
ined by flow cytometry. Data are mean6 standard error
of the mean (s.e.m.)for five donors (AIH), three donors
(PSC) and five donors (liver).
Fig. S5. Sustained exposure to low dose interleukin
(IL)22 up-regulates signal transducer and activator of
transcription-5 (STAT-5) selectively in
CD41CD251CD1271 T cells as well as in regulatory T
cells (Treg). Peripheral blood mononuclear cells (PBMCs)
from patients with autoimmune liver disease (AILD) were
stimulated for 18 h with IL-2 (Proleukin) doses of 0, 1, 5
and 10 IU/ml and expression of phosphorylated
(Y694)STAT-5 by each leucocyte population assessed by
flow cytometry. (a) Percentage of each leucocyte popula-
tion expressing pSTAT-5 at each IL-2 dose. (b) median
fluorescence intensity (MFI) for pSTAT-5.
Fig. S6. Effect of very low dose interleukin (IL)22 on the
suppressive ability of regulatory T cells (Treg) in auto-
immune liver diseases. (a) CD41CD25– T responder cells
were isolated from peripheral blood mononuclear cells
(PBMCs) of controls (n 5 3) and the effect of blocking
CD28-mediated co-stimulation with Abatacept [cytotoxic
T lymphocyte antigen-4-immunoglobulin (CTLA-4-Ig)]
on division index at 5 days examined. (B)
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CD41CD251CD127– Treg and autologous CD4
1CD25– T
responder cells were isolated from PBMC of two patients
with autoimmune hepatitis (AIH) (one in remission and
one in relapse). T responders were labelled with cell trace
violet, and following overnight exposure of Treg to 0 or 5
IU/ml Proleukin were co-cultured with the Treg in the
presence of anti-CD3 and dendritic cells, with or without
CTLA-4 blockade. Cell trace violet dilution indicating T
responder cell division was analysed by flow cytometry at
5 days.
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